Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 28 October 1988:
Vol. 242. no. 4878, pp. 574 - 577
DOI: 10.1126/science.2902690
Prev | Table of Contents | Next

Articles

Science, Vol 242, Issue 4878, 574-577
Copyright © 1988 by American Association for the Advancement of Science

articles

Limited immunological recognition of critical malaria vaccine candidate antigens

MF Good, LH Miller, S Kumar, IA Quakyi, D Keister, JH Adams, B Moss, JA Berzofsky, and R Carter

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

Current vaccine development strategies for malaria depend on widespread immunological responsiveness to candidate antigens such as the zygote surface antigens and the sporozoite coat protein, the circumsporozoite (CS) protein. Since immunological responsiveness is controlled mainly by genes mapping within the major histocompatibility complex (MHC), the humoral immune response to the zygote surface antigens and the cytotoxic T lymphocyte (CTL) response to the CS protein were examined in MHC-disparate congenic mouse strains. Only two of six strains responded to the 230-kilodalton zygote surface antigen and another two strains responded to the 48/45-kilodalton surface antigen. From two mouse strains, expressing between them five different class I MHC molecules, there was recognition of only a single CTL epitope from the CS protein, which was from a polymorphic segment of the molecule. The restricted CTL response to this protein parallels the restricted antibody response to this protein observed in humans and mice. These findings suggest that subunit malaria vaccines now being developed may be ineffective.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-{gamma}.
P. Sun, R. Schwenk, K. White, J. A. Stoute, J. Cohen, W. R. Ballou, G. Voss, K. E. Kester, D. G. Heppner, and U. Krzych (2003)
J. Immunol. 171, 6961-6967
   Abstract »    Full Text »    PDF »
A Longitudinal Study of Human Antibody Responses to Plasmodium falciparum Rhoptry-Associated Protein 1 in a Region of Seasonal and Unstable Malaria Transmission.
P. N. Fonjungo, I. M. Elhassan, D. R. Cavanagh, T. G. Theander, L. Hviid, C. Roper, D. E. Arnot, and J. S. McBride (1999)
Infect. Immun. 67, 2975-2985
   Abstract »    Full Text »    PDF »
Transgenic Expression of a Mosquito-Stage Malarial Protein, Pbs21, in Blood Stages of Transformed Plasmodium berghei and Induction of an Immune Response upon Infection.
G. Margos, M. R. van Dijk, J. Ramesar, C. J. Janse, A. P. Waters, and R. E. Sinden (1998)
Infect. Immun. 66, 3884-3891
   Abstract »    Full Text »    PDF »
Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus.
D. Kaslow, S. Isaacs, I. Quakyi, R. Gwadz, B Moss, and D. Keister (1991)
Science 252, 1310-1313
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)